Physician profile

Tiffani T Phan

Obstetrics & Gynecology · San Diego, CA

NPI 1134515695

$250.33

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$83.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Hologic Sales and Service, LLC $57.04 2019-2024 Aptima
Minerva Surgical, INC $53.24 2019
Astellas Pharma US INC $26.39 2024 Veozah
Evofem Biosciences, INC. $21.74 2021
Merck Sharp & Dohme LLC $18.15 2020
Phadia US INC. $17.40 2020
Abbvie INC. $16.24 2019
Lupin INC. $14.67 2019
Bayer Healthcare Pharmaceuticals INC. $13.39 2024
Avion Pharmaceuticals $12.07 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tiffani T Phan

$250.33

in general payments reported 2019-2025

Years
2019-2024
Top company
Hologic Sales and Service, LLC

https://glasscript.com/doctor/5969147/tiffani-t-phan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.